Nutchavadee Vorasan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nutchavadee Vorasan has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Chonlada Inmongkol
Center of Research Excellence for Neuromuscular Diseases, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
1 shared publication - Ekkarat Wongsawat
Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Mahidol University
1 shared publication - Joshua Burns
Department of Epidemiology and Cancer Control St. Jude Children's Research Hospital Memphis Tennessee USA
1 shared publication - Nasikarn Angkasekwinai
Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University
1 shared publication - Niramon Sereephaowong
Center of Research Excellence for Neuromuscular Diseases, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
1 shared publication - Oranee Sanmaneechai
Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
1 shared publication
Latest Publications
- Open Access
- 21 April 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Axonal-demyelinating differences in functional change in pediatric Charcot–Marie–Tooth and related neuropathies
Charcot–Marie–Tooth disease and related neuropathies (CMTR) are heterogeneous inherited neuropathies with variable progression, yet data on ped
- 21 April 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Open AccessAxonal-demyelinating differences in functional change in pediatric Charcot–Marie–Tooth and related neuropathies
Charcot–Marie–Tooth disease and related neuropathies (CMTR) are heterogeneous inherited neuropathies with variable progression, yet data on ped
- Open Access
- 12 November 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2565446
Clinical course and outcomes of patients with anti-interferon-gamma autoantibody-associated adult-onset immunodeficiency: an observational cohort study
Anti-interferon-gamma autoantibody (anti-IFN-γ-auto-Abs)-associated adult-onset immunodeficiency (AOID) syndrome presents with variable clinical manifestations, and long-term outcome data and natural history remain limited. This single-center study utilized a disease registry of AOID patients (≥18 years) at Siriraj Hospital, Bangkok, Thailand. Clinical outcomes (survival, death, loss to follow-up) as of November 20, 2024 and disease status (remission, non-remission) at each visit were analyzed. A total of 65 patients were recorded over an eight-year period between 2017 and 2024. The mean age of all patients was 56.4 years, and 66% were female. At initial presentation, 95 opportunistic infections were isolated from 61 patients. M. abscessus (44.2%) was the predominant pathogens, followed by M. avium complex (13.7%), salmonellosis (9.5%) and M. tuberculosis (8.4%). Among 53 patients with at least one year of follow-up, 12 (22.6%) achieved remission and 41 (77.4%) remained in non-remission. Antibody levels exhibited a significant decline over time (p < 0.05) across all patients. However, no significant difference in antibody levels was observed between remission and non-remission group (p > 0.05). Notably, median baseline and latest antibody concentration were significantly lower in the remission group compared to the non-remission group, respectively (baseline level: 3.5, IQR 2.8-3.8 vs. 4.0, IQR 3.5-4.2, p = 0.030; latest level: 2.1, IQR 1.8-2.4 vs. 3.0, IQR 2.1-3.6, p = 0.044). This study noted a slight shift in pathogen distribution, even though rapidly growing mycobacteria remain the most common infection. Most patients experienced non-remission, necessitating prolonged antimicrobial therapy. Our findings indicate a declining trend in antibody levels over time. Given the high rates of non-remission and the associated need for extended treatment, immunomodulatory agents should be considered, especially for non-remission patients, to potentially reduce antibody levels and the risk of infection recurrence.
- 12 November 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2565446
Open AccessClinical course and outcomes of patients with anti-interferon-gamma autoantibody-associated adult-onset immunodeficiency: an observational cohort study
Anti-interferon-gamma autoantibody (anti-IFN-γ-auto-Abs)-associated adult-onset immunodeficiency (AOID) syndrome presents with variable clinical manifestations, and long-term outcome data and natural history remain limited. This single-center study utilized a disease registry of AOID patients (≥18 years) at Siriraj Hospital, Bangkok, Thailand. Clinical outcomes (survival, death, loss to follow-up) as of November 20, 2024 and disease status (remission, non-remission) at each visit were analyzed. A total of 65 patients were recorded over an eight-year period between 2017 and 2024. The mean age of all patients was 56.4 years, and 66% were female. At initial presentation, 95 opportunistic infections were isolated from 61 patients. M. abscessus (44.2%) was the predominant pathogens, followed by M. avium complex (13.7%), salmonellosis (9.5%) and M. tuberculosis (8.4%). Among 53 patients with at least one year of follow-up, 12 (22.6%) achieved remission and 41 (77.4%) remained in non-remission. Antibody levels exhibited a significant decline over time (p < 0.05) across all patients. However, no significant difference in antibody levels was observed between remission and non-remission group (p > 0.05). Notably, median baseline and latest antibody concentration were significantly lower in the remission group compared to the non-remission group, respectively (baseline level: 3.5, IQR 2.8-3.8 vs. 4.0, IQR 3.5-4.2, p = 0.030; latest level: 2.1, IQR 1.8-2.4 vs. 3.0, IQR 2.1-3.6, p = 0.044). This study noted a slight shift in pathogen distribution, even though rapidly growing mycobacteria remain the most common infection. Most patients experienced non-remission, necessitating prolonged antimicrobial therapy. Our findings indicate a declining trend in antibody levels over time. Given the high rates of non-remission and the associated need for extended treatment, immunomodulatory agents should be considered, especially for non-remission patients, to potentially reduce antibody levels and the risk of infection recurrence.